Colistimethate Sodium Efficacy and Safety in Treating Carbapenem-Resistant Infections

A prospective observational study of 222 patients aged 14 and older with culture-confirmed carbapenem-resistant Gram-negative bacilli infections, treated with intravenous colistimethate sodium for at least 7 days. The research was conducted in nine ICUs in Henan Province, China, between November 2021 and November 2023. It reports clinical response rates, 30-day mortality, and incidence of acute kidney injury.

Use Cases

• Modeling risk factors for poor clinical response based on APACHE II scores, infection site, and microbial profile.
• Analyzing the association between baseline serum creatinine and the risk of acute kidney injury as a safety endpoint.
• Comparing clinical efficacy outcomes between patients with single-site versus multi-site infections.
• Evaluating mortality predictors in ICU patients with carbapenem-resistant infections.

Strengths

• Data is from a prospective observational study of 222 consecutively enrolled patients.
• Reports specific efficacy metrics, including an 82.5% clinical response rate and 19.8% 30-day all-cause mortality.
• Includes detailed safety outcomes, such as a 20.4% incidence of acute kidney injury, mostly KDIGO stage I.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data reflects a specific geographic and temporal context (Henan Province, China, 2021-2023), which may limit generalizability.

Provenance

Source

figshare

Collection Method

Prospective observational study conducted in nine ICUs.

Time Range

November 2021 to November 2023

Freshness

Last updated 2026-05-29 04:45:28; freshness should be verified.

Geography

Henan Province, China